Myeloid-Derived Suppressor Cells in Trypanosoma cruzi Infection

Manuel Fresno1,2* and Núria Gironès1,2*

1 Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain, 2 Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Group 12, Madrid, Spain

Myeloid-derived suppressor cells (MDSCs) are immature heterogeneous myeloid cells that expand in pathologic conditions as cancer, trauma, and infection. Although characterization of MDSCs is continuously revisited, the best feature is their suppressor activity. There are many markers for MDSC identification, it is distinctive that they express inducible nitric oxide synthase (iNOS) and arginase 1, which can mediate immune suppression. MDSCs can have a medullary origin as a result of emergency myelopoiesis, but also can have an extramedullary origin. Early studies on Trypanosoma cruzi infection showed severe immunosuppression, and several mechanisms involving parasite antigens and host cell mediators were described as inhibition of IL-2 and IL-2R. Another mechanism of immunosuppression involving tumor necrosis factor/interferon γ-dependent nitric oxide production by inducible nitric oxide synthase was also described. Moreover, other studies showed that nitric oxide was produced by CD11b+ Gr-1+ MDSCs in the spleen, and later iNOS and arginase 1 expressed in CD11b+Ly6C+Ly6Glo monocytic MDSC were found in spleen and heart of T. cruzi infected mice that suppressed T cell proliferation. Uncontrolled expansion of monocytic MDSC leads to L-arginine depletion which hinders nitric oxide production leading to death. Supplement of L-arginine partially reverts L-arginine depletion and survival, suggesting that L-arginine could be administered along with anti-parasitical drugs. On the other hand, pharmacological inhibition of MDSCs leads to death in mice, suggesting that some expansion of MDSCs is needed for an efficient immune response.

The role of signaling molecules mediating immune suppression as reactive oxygen species, reactive nitrogen species, as well as prostaglandin E2, characteristics of MDSCs, in T. cruzi infection is not fully understood. We review and discuss the role of these reactive species mediators produced by MDSCs. Finally, we discuss the latest results that link the SLAMF1 immune receptor with reactive oxygen species. Interaction of the parasite with the SLAMF1 modulates parasite virulence through myeloid cell infectivity and reactive oxygen species production. We discuss the possible strategies for targeting MDSCs and SLAMF1 receptor in acute Trypanosoma cruzi infection in mice, to evaluate a possible translational application in human acute infections.

Keywords: myeloid-derived suppressor cells, Trypanosoma cruzi, arginase 1, inducible nitric oxide synthase, L-arginine, SLAMF1, ROS, RNS
MDSCs

The existence of populations of immature myeloid suppressor cells was described in different murine models of immune suppression and cancer (Angulo et al., 2000; Kusmartsev et al., 2000), among others, and associated with the production of nitric oxide (NO) and other reactive nitrogen species (RNS). To distinguish them from normal immature myeloid cells (IMCs) that give rise to granulocytes, macrophages, and dendritic cells, they were named as myeloid-derived suppressor cells, and abbreviated first as MSCs (Sinha et al., 2005) and later as MDSCs (Gabrilovich et al., 2017). MDSCs are a heterogeneous population of CD11b+Gr-1+ cells including myeloid progenitors and IMCs that expand and accumulate during tumor growth, trauma, acute and chronic immune responses to pathogens, and other altered immune responses (Gabrilovich and Nagaraj, 2009). However, this population is best defined by their suppressor activity (Bronte et al., 2016), which differentiates them from normal IMCs. MDSCs show important phenotypic differences depending on the anatomical site where they are located or the pathological condition. In addition, in tumor-induced MDSCs, discrete subpopulations with distinct T cell suppressive activity have been identified (Marigo et al., 2008; Movahedi et al., 2008).

Identification of MDSCs Subsets

Initially, MDSCs were identified using anti-Gr-1 antibodies that recognized both, Ly6G and Ly6C, surface molecules. Later, the use of antibodies specific for Ly6C and Ly6G surface antigens allowed the classification of MDSCs in monocytic CD11b+Ly6C−Ly6G- (M-MDSCs) and polymorphonuclear CD11b+Ly6C+Ly6G+ (PMN-MDSCs), also named granulocytic MDSCs (G-MDSCs). M-MDSCs share some features of classical (CAM or M1) and alternatively activated (AAM or M2) macrophages. M1 are induced by proinflammatory cytokines such as IFN-γ, which express inducible nitric oxide synthase (iNOS). Some subsets of M2 macrophages that are induced by anti-inflammatory cytokines such as IL-4 and IL-13, express arginase 1 (Arg1). However, MDSCs express both enzymes (Gabrilovich and Nagaraj, 2009). There are other characteristics of M-MDSCs besides iNOS and Arg1, as production of prostaglandin E2 (PGE2), and expression of Transforming growth factor β (TGF-β), Interleukin 4 receptor α (IL-4Rα), and IL-13. On the other hand, PMN-MDSCs express RAR-related orphan receptor gamma 1 (RORC1), NADPH oxidase (NOX)-2, and granulocyte-colony stimulating factor (G-CSF). Finally, there are some markers common to both subsets as Phospho-Signal transducer and activator of transcription 3 (STAT3), CCAAT enhancer-binding protein beta (c/EBP/β), S100 calcium-binding proteins (S100A8 and S100A9), Programmed death-ligand 1 (PD-L1), IL-10, granulocyte-macrophages colony-stimulating factor (GM-CSF), IL-1 (Bronte et al., 2016), and indoleamine 2,3-dioxygenase (IDO) (Zhao et al., 2016). Because some of those markers are not exclusive of MDSCs, the best probe of bona fide MDSCs is their ability to suppress T cell proliferation. However, it was proposed that subsets expressing MDSC markers that do not suppress proliferation should be described as MDSC-like cells (MDSC-LC) (Bronte et al., 2016).

Suppressor Mechanisms of MDSCs

Some of the main mechanisms of suppression of T cell proliferation by MDSC are outlined in Figure 1. iNOS and Arg1 use L-arginine (L-arg) as a substrate for their enzymatic activities. Extracellular L-arg is transported to the cytoplasm through cationic amino acid transporter 2B (CAT2B). iNOS converts L-arg into NO which is toxic for microbes, and citrulline. Arg1 converts L-arg into urea and L-ornithine, which in turn is converted into polyamines involved in cell growth and differentiation, and L-proline that affects collagen production, tissue repair, and fibrosis (Bronte and Zanovello, 2005). L-arg is a semi-essential amino acid in adult mammals and it is required in the diet to maintain adequate levels in some stressed conditions as pregnancy, trauma, or infection (Bronte and Zanovello, 2005). In addition, T cell proliferation is extremely sensitive to extracellular L-arg concentration. Thus, the threshold of L-arg concentration in mammalian plasma that permits fully functional T cell proliferation is in the order of 100 μM (Choi et al., 2009). Moreover, the combined activity of Arg1 and iNOS enzymes is important in the suppressive activity of mouse MDSCs in tumors (Bronte et al., 2003).

MDSCs use several mechanisms to suppress the T cell response, such as triggering apoptosis of activated T cells by depleting of L-arg, via Arg1 (Apolloni et al., 2000). L-arg depletion also causes translational blockade of the ζ-chain of CD3, possibly through pathways that involve the kinases general control non-depressible 2 (GCN2) and mammalian target of rapamycin (mTOR) (Bronte and Zanovello, 2005). There is evidence that T cell suppression mediated by MDSCs is antigen-specific, this is because MDSCs can take up microbial antigens, process them, and present them to CD8+ T cells (Movahedi et al., 2008; Youn et al., 2008), thus, MDSCs can directly suppress CD8+ T cells after peptide presentation by MHCI to the T cell receptor (TCR). There is also evidence that MDSCs may suppress immune activation by inducing T regulatory cell expansion (Huang et al., 2006). Other suppressive mechanisms that have been proposed include the production of TGF-β, depletion of cysteine, induction of Cyclooxygenase-2 (COX-2) expression, and PGE2 production (Ostrand-Rosenberg, 2010).

Besides, iNOS produces NO, which causes nitrosylation of cysteine residues in target proteins and production of cyclic GMP (cGMP) by the soluble guanylate cyclase (sGC) pathway. These events interfere with the interleukin-2 receptor (IL-2R)-signaling pathway by blocking the phosphorylation of signal-transducing molecules that are coupled to IL-2R and by altering the stability of mRNA encoding IL-2 (Bronte and Zanovello, 2005).

When L-arginine concentrations are limiting due to Arg1 activity, and iNOS levels are high, electrons can be transferred by iNOS subunits to the co-substrate oxygen (O2), which generates superoxide anion (O2·−), a reactive oxygen species (ROS). Other sources of O2·− may come from NADPH oxidase-2 (NOX-2) activity in other MDSC subsets. NOX-2 is a multi-subunit...
enzyme with membrane and cytosolic components, which actively communicate during the host responses to a wide variety of stimuli and mediates ROS production, which has an important role in the elimination of invading microorganisms in macrophages and neutrophils (Panday et al., 2015) and also expressed by PMN-MDSCs (Bronte et al., 2016). 

$\text{O}_2^-$ can combine either with NO to generate peroxynitrites (ONOO$^-$) or with water (H$_2$O) to produce hydrogen peroxide (H$_2$O$_2$) (Bronte and Zanovello, 2005). Then, ONOO$^-$ causes nitration of proteins in tyrosine residues interfering with multiple signals, which together with H$_2$O$_2$ induce apoptosis (Bronte and Zanovello, 2005).

Activation of the enzyme indoleamine 2,3-Dioxygenase (IDO), which converts L-tryptophan to L-kynurenine causes depletion of extracellular L-arginine which inhibits CD3 $\zeta$-chain expression interfering with TCR signaling. Arg1 together with INOS consume extracellular L-arginine which inhibits CD3 $\zeta$-chain expression interfering with TCR signaling. Arg1 produces L-ornithine that is the substrate of polyamines linked to proliferation and collagen involved in tissue repair and fibrosis. Cyclooxygenase 2 (COX-2) and microsomal prostaglandin E2 synthase (mPGES-1) produce suppressive prostaglandin E2 (PGE$_2$). Indoleamine 2,3-Dioxygenase (IDO) converts L-tryptophan into L-kynurenine which also blocks T cell proliferation.

FIGURE 1 | Main mechanisms of T cell immune suppression mediated by MDSCs. Suppressive action of iNOS and NADPH oxidase 2 (NOX-2) by RNS and reactive oxygen species (ROS) generation mediated by protein nitration and nitrosylation leads to apoptosis and inhibition of protein phosphorylation and IL-2 mRNA degradation. Arg1 together with INOS consume extracellular L-arginine which inhibits CD3 $\zeta$-chain expression interfering with TCR signaling. Arg1 produces L-ornithine that is the substrate of polyamines linked to proliferation and collagen involved in tissue repair and fibrosis. Cyclooxygenase 2 (COX-2) and microsomal prostaglandin E2 synthase (mPGES-1) produce suppressive prostaglandin E2 (PGE$_2$). Indoleamine 2,3-Dioxygenase (IDO) converts L-tryptophan into L-kynurenine which also blocks T cell proliferation.

Origin of MDSC

In severe systemic infections, there are profound alterations in the hematopoietic function of the BM that likely reflect a homeostatic response to a decrease in circulating immune populations (Glatman Zaretsky et al., 2014). Hematopoietic progenitors in the BM can sense the presence of pathogens through pattern recognition receptors, as Toll-like receptors (TLRs), or in response to proinflammatory cytokine stimuli leading to an increased generation of granulocyte-macrophage precursors (GMPs) and common myeloid precursors (CMPs), which then expand and further differentiate towards neutrophils facilitating what is called “emergency myelopoiesis”, at the expense of erythroid and lymphoid differentiation (Mitroulis et al., 2018), or giving rise to immature neutrophils that migrate to peripheral tissues (Evard et al., 2018).

Although there is a consensus that all MDSC derive from the same precursors, there is a controversy about their medullary or extramedullary origin. The origin (and appearance) of MDSCs in each particular physiopathological context is different and not
completely understood. Elevated levels of colony-stimulating factors (CSFs) may induce emergency myelopoiesis (Panopoulos and Watowich, 2008) that produces migration of IMCs from BM before their full differentiation, to replace cells consumed during inflammation, in particular, due to infection (Cheers et al., 1988; Kawakami et al., 1990).

The classical hypothesis to explain MDSCs generation by emergency myelopoiesis is known as the “two signal model” (Condamine et al., 2015), where signal 1 is given by GM-CSF, G-CSF, and IL-6, that mobilizes IMCs from bone marrow which is also called “emergency granulo-monocytopoiesis” (Strauss et al., 2003). Signal 2 is mainly mediated by Toll-like receptor signals that signal through NFkappaB for cytokine production (Gabrilovich and Nagaraj, 2009; Condamine et al., 2015). After leaving the bone marrow, IMCs can become MDSCs in the spleen, where extramedullary myelopoiesis can occur (Song et al., 2005). Thus, it is also feasible that expansion of MDSCs occurs in secondary lymphoid organs.

In the context of cancer therapy, there are many approaches to target MDSCs (reviewed by Gabrilovich, 2017) Which could be assayed for T. cruzi and other infectious diseases where they play a detrimental role. MDSCs can be eliminated with gemcitabine and 5-fluourouracil (5FU) chemotherapy, and inhibiting the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor and S100A9. But also targeting the suppressive machinery by inhibiting phosphodiesterase type 5 (PDE-5), COX-2, and Class I Histone deacetylase (HDAC). Besides, upregulation of the nuclear factor erythroid 2-related factor 2 (Nrf2) with synthetic triterpenoids reduces MDSCs suppressive activity. Other approaches targeted MDSCs expansion and differentiation as treatment with all-trans-retinoic acid (ATRA), inhibition of STAT3, and treatment with phospholipid phosphatidylserine (PS) antibodies. In addition, microRNA networks that regulate the differentiation, expansion, and suppression function of MDSCs may provide a novel potential approach for targeting MDSCs in the tumor environment (Su et al., 2019).

**Trypanosoma cruzi INFECTION**

*Trypanosoma cruzi* is a unicellular protozoan parasite that causes the Chagas disease or American Trypanosomiasis, a chronic debilitating condition endemic of Latin America, and a neglected tropical disease (Perez-Molina and Molina, 2018). Nowadays, it has been estimated that there are around 6–7 million chronically infected people [World Health Organization Chagas Disease (American trypanosomiasis)]. This parasite has a very complex life cycle that includes an invertebrate hematophagous *Reduviidae* insect vector and multiple mammalian hosts (Clayton, 2010). Also, *T. cruzi* has different vital stages (de Souza et al., 2010; Rodrigues et al., 2014). The non-infective epimastigotes are present in the midgut of triatomines insect vectors where they differentiate into infective metacyclic trypomastigotes, that after the infection of host cells are differentiated into the intracellular replicative amastigote form. After replication amastigotes differentiate to infective trypomastigotes that reach the bloodstream after cell lysis (Echeverria and Morillo, 2019). Chagas disease presents an acute phase with low mortality and symptomatology. Then, the patients can remain in an asymptomatic chronic phase for life or in the 30–40% of cases and after 10–30 years after infection may develop chronic myocarditis and cardiomyalgia, or megavisceras (megaoesophagus or megacolon) or both (Rassi et al., 2012).

**Immune Suppression in Trypanosoma cruzi Infection**

Early reports from the 70-80s showed that infection with *T. cruzi* is associated with severe unresponsiveness to mitogens and antigens during the acute phase of the disease. It was thought that a suppressor factor was the cause (Cunningham et al., 1978; Kierszenbaum, 1982). Moreover, other reports pointed out T cells (Tarleton, 1988a; Guimarães-Pinto et al., 2018), including γδ T cells (Cardillo et al., 1998), as well as adherent cells (Kierszenbaum, 1982; Motran et al., 1996) as suppressor cells. In addition, inhibition of Interleukin (IL)-2 synthesis (Harel-Bellan et al., 1985; Tarleton, 1988a) and reduced cell surface expression of IL-2 receptor by activated spleen cells (SC) from infected mice (Lopez et al., 1993), explained this unresponsiveness. By contrast, activated SC from infected mice produced elevated levels of Interferon-γ (IFN-γ) and tumor necrosis factor (TNF) (Tarleton, 1988b; Nabors and Tarleton, 1991). Also, cross-reactive autoantibodies against AGC10 membrane glycoprotein were present in chagasic sera could also suppress the proliferation of human T lymphocytes (Hernández-Munain et al., 1992) by a mechanism preceding translation of IL-2 and its high-affinity receptor subunits (Kierszenbaum et al., 2002). Moreover, AGC10 was able to inhibit T cell activation, IL-2R, and IL-2 transcription through L-selectin (Kierszenbaum et al., 1999; Alcaide and Fresno, 2004). Other soluble substances, including suppressive cytokines as transforming growth factor-β (TGF-β), IL-4, IL-10, and prostaglandins, released upon contact with parasite-antigens, have also been proposed as the cause of *T. cruzi* immunosuppression (Kierszenbaum, 1982; Tarleton, 1988a; Fernandez-Gomez et al., 1998; Hansen et al., 1998; Pinge-Filho et al., 1999). In particular, IL-12 produced by macrophages in response to infection mediated resistance to *T. cruzi* (Aliberti et al., 1996).

**MDSCs and Infection**

It was proposed that inhibition of T cell proliferation in *T. cruzi*-infected mice takes place through IFN-γ and NO secretion (Abrahamsohn and Coffman, 1995). *In vitro* studies identified TH1 cell-derived TNF and IFN-γ as the most important cytokines involved in the killing of intracellular *T. cruzi* through a NO-mediated L-arginine- dependent killing mechanism (Gazzinelli et al., 1992; Muñoz-Fernández et al., 1992b). This was corroborated *in vivo* since anti-IFN-γ administration resulted in a drastic increase in parasitemia and mortality (Torrico et al., 1991; Silva et al., 1992). Other studies showed that NO played a role in host resistance to *T. cruzi* infection in mice (Petray et al., 1993).

We were the first to clearly describe CD11b+Gr-1+ MSCs (later re-named as MDSCs) in the spleen on infected *T. cruzi*.
mice that mediated T cell suppression through the production of NO (Goñi et al., 2002). Moreover, this finding of MDSC suppressor activity mediated by NO was the earliest described in the context of any infection. Later we found that M-MDSCs infiltrate target organs like the heart during T. cruzi infection (Cuervo et al., 2011).

Since then MDSCs were found in many infections caused by viral, bacterial, and protozoan parasitic pathogens. Thus, among them, human immunodeficiency virus, Cytomegalovirus, hepatitis B, and hepatitis C viruses impaired lymphocyte function. Similar results were found in bacterial infections by Staphylococcus aureus, Francisella tularensis, Mycobacterium spp., Klebsiella pneumonieae, Helicobacter pylori, Esherichia coli, and polymicrobial sepsis (reviewed in Dorhoi and Du Plessis, 2017).

Medullary or extramedullary myelopoiesis may explain the expansion of MDSCs in other protozoan parasitic infections (reviewed by Van Ginderachter et al., 2010). For instance, in Leishmania major infection undifferentiated macrophage-granulocytes mediated susceptibility of BALB/c mice (Mirkovich et al., 1986), but others found that MDSCs were protective (Pereira et al., 2011). However, the genetic background defines MDSC differentiation where L. major parasites can modulate the suppressive effect of MDSCs in a strain-dependent manner (Schmid et al., 2014). Besides, in L. donovani infection there was enhanced myelopoiesis involving GM-CSF and TNF-α (Cotterell et al., 2000). Other authors also found that L. donovani induces hematopoietic stem cells (HSC) expansion and skews their differentiation towards non-classical myeloid progenitors with a regulatory phenotype (Bandyopadhyay et al., 2015), suggesting that emergency hematopoiesis contributes to the pathogenesis of visceral leishmaniasis, as decreased hematopoietic stem cells (HSCs) expansion results in a lower parasite burden (Abidin et al., 2017). Thus, MDSCs in leishmaniosis may play an important role, although it depends on the magnitude of the expansion in different experimental models.

In Plasmodium chabaudi nonlethal infection, splenic expansion of CD11b+ Gr-1+ cells was also observed (Sponaas et al., 2009), and also the emergence of atypical progenitors that had both lymphoid and myeloid potential with a strong bias toward the generation of myeloid cells in vivo (Belyaev et al., 2010). Finally, after Toxoplasma gondii infection Gr-1+MDSCs played a regulatory protective role (Voisin et al., 2004; Dunay et al., 2008).

**MDSCs in Trypanosoma cruzi Infection**

Some of the main mechanisms of suppression of T cell proliferation by MDSC in T. cruzi infection are outlined in Figure 2.

We have described that during acute T. cruzi infection of BALB/c mice infected with the Y strain, the cardiac inflammatory infiltrate involves CD11b+Ly6C+Ly6Glo M-MDSC expressing Arg1 and iNOS, which suppressed T cell proliferation (Cuervo et al., 2008; Cuervo et al., 2011; Carbajosa et al., 2018). Using two mouse strains with different

---

**FIGURE 2 |** MDSCs suppressive mechanisms in the context of T. cruzi infection and SLAMF1 receptor. As outlined in Figure 1, enzymes as iNOS, NOX-2, COX-2, and Arg1 mediate suppression in MDSCs. These enzymes are involved in the response against T. cruzi infection. In addition, we incorporated the SLAMF1 receptor interacting with T. cruzi which through the EAT2 adaptor can trigger the conversion of PI to PI3P activating NOX-2. Question marks indicate those processes that need to be further explored.
genetic backgrounds and responses to infection, C57BL/6, and BALB/c, M-MDSCs were expanded with greater magnitude in BALB/c mice, which died within one month post-infection. But C57BL/6 mice showed a high percentage of survival, indirectly confirming the relationship with M-MDSC appearance with pathogenicity in acute *T. cruzi* infection. On the other hand, Arocena et al. (2014) found a new facet of MDSCs as regulators of inflammation while reducing parasite burden. They documented a higher number of MDSCs in the spleens and livers of infected BALB/c mice compared with C57BL/6 mice during acute infection. Also, mechanistic studies demonstrated that ROS and NO were involved in the suppressive activity of MDSCs, with high expression of NOX-2 and phosphorylation of signal transducer and activator of transcription-3 (STAT3). Moreover, in vivo depletion of MDSCs with 5-fluorouracil (5FU) led to an increased production of IL-6, IFN-γ, and a Th17 response associated with very high parasitemia and mortality in C57BL/6 (Arocena et al., 2014). Thus, the results suggest that the role of MDSCs depends on host and parasite genetic backgrounds, which condition the targeting of different organs during infection. Those authors found that IL-6 signaling leads to the phosphorylation of the STAT3, which, in other contexts, plays a critical role in the accumulation of immature myeloid cells (Nefedova et al., 2004).

In our studies also the expansion of MDSCs was preceded by higher levels of IL-6 in susceptible mice compared to non-susceptible (Sanoja et al., 2013). In addition, we demonstrated the presence of cardiac M-MDSCs cells in infected BALB/c mice, which significantly contributed to heart leukocyte infiltration, that besides iNOS and Arg1, expressed COX-2 and mPGES-1 and produced PGE₂, chemokines, and inflammatory cytokines, suggesting that COX-2 is detrimental for the host (Guerrero et al., 2015).

Likewise, we found in infected heart tissue non-suppressor PMN-MDSCs that did not express iNOS nor Arg1 but expressed S100A8/9 MDSC markers (Cuervo et al., 2011), and thus, they should be classified as MDSC-LC according to the latest nomenclature recommendations (Bronte et al., 2016). S100A8/9 are involved in leukocyte recruitment and inducing cytokine secretion (Wang et al., 2018), and could be attracting M-MDSCs to heart tissue (Cuervo et al., 2011). Notably, M-MDSCs expansion was linked to local and systemic extracellular L-arg depletion, likely involved in immunosuppression, which reduced NO production by iNOS due to substrate depletion. More importantly, L-arg supplementation to infected mice almost restored plasma L-arg and NO levels, significantly decreased parasitemia, heart parasite burden, and improved clinical status, while increasing mice survival and cardiac performance (Carbajosa et al., 2018). Similar results were recently obtained by others (Bianchini Narde et al., 2021). However, paradoxically, they also found promoted collagenogenesis in the heart muscle tissue suggesting that further analysis of cardiac function is needed to clarify the effect of arginine treatment under the evolution of Chagas cardiomyopathy. On the other hand, L-arg supplementation was beneficial in preventing vertical transmission in infected rats (da Costa et al., 2014).

Interestingly, we found elevated levels of asymmetric + symmetric dimethylarginine (ADMA + SDMA) in heart tissue and plasma of *T. cruzi* infected mice (Carbajosa et al., 2018). ADMA is a product of nuclear proteolysis by arginine methyltransferases (Teerlink, 2005), and is an endogenous inhibitor of iNOS that in combination with L-arg can regulate iNOS activity (Blackwell, 2010). Thus, despite INOS expression is elevated, its activity could be inhibited by the combination of low L-arg as substrate and high levels of ADMA inhibitor (Carbajosa et al., 2018). Interestingly, a low L-arg/ADMA ratio is a predictor of NO bioavailability and mortality in Dilated Cardiomyopathy, a pathology that resembles Chronic Chagasic Cardiomyopathy (CCC) suggesting a possible relation between L-arg/ADMA levels and CCC (Carbajosa et al., 2018).

In this direction, since Arg1 is induced in M2 macrophages by IL-4 and IL-13 through IL-4Rα, transgenic mice overexpressing IL-13 were much more susceptible to *T. cruzi* infection and this correlated with the increased expression of Arg1, but also ADMA (Abad Dar and Hölscher, 2018). More importantly, the death of IL-13 transgenic animals due to infection was blocked by the administration of Arg1 inhibitors. Thus the authors discuss that IL-4Rα-induced Arg1 mediates susceptibility to acute experimental Chagas disease by several — mutually not exclusive — mechanisms downstream of Arg-1 including L-arginine depletion in MDSCs and M2 macrophages and polyamine synthesis.

On the other hand, the enzyme IDO, which metabolizes L-tryptophan to L-kynurenine, is critical for host resistance against *T. cruzi* (Knubel et al., 2010). Moreover, the tryptophan metabolite 3-hydroxykynurenine was active against *T. cruzi* and prevented the inflammatory pathology from preventing the clinical symptoms of chronic Chagas disease (Knubel et al., 2011; Knubel et al., 2017). We found by a global metabolomic study that in the experimental *T. cruzi* acute infection circulating and heart tissue levels of L-kynurenine were incremented, but L-tryptophan remained stable (Gironès et al., 2014). Since in our model of acute infection MDSCs there is a huge expansion of MDSCs, tryptophan metabolism in MDSCs infiltrating the heart may be also involved in the immunosuppression.

In addition, inflammatory monocyte-derived dendritic cells (moDCs) were found in the skin of C57BL/6 mice after intradermal inoculation with *T. cruzi* RA strain, produced TNF-α and NO, but also IL-10 and displayed a poor capacity to induce lymphoproliferation. But, ablation of Mo-DCs by treatment with 5FU confirmed their dual role during infection, limiting the parasite load by iNOS-related mechanisms and negatively affecting the development of anti-parasite T-cell response. The authors demonstrated that these cells not only control parasite spreading but also its persistence in the host (Poncini and González-Cappa, 2017). Thus, in the skin mo-DCs may play a regulatory role.

Notably, immunization of BALB/c mice with *T. cruzi* trans-sialidase protected them from infection with the Tulahuen strain of *T. cruzi* and significantly reduced the expansion of PMN-MDSCs (Prochetto et al., 2017). On the other hand, targeting MDSCs by 5FU administration before each dose of trans-sialidase-based vaccine (TSf-ISPA) was able to significantly
ampliorate survival and decrease parasitemia levels of TSf-ISP A-vaccinated and infected mice (Gamba et al., 2021). However, the detrimental role of MDSCs in T. cruzi infection may be assumed in some models, in others, their depletion results in high mortality, and some questions are raised about whether they should be considered in vaccine design (Cabrera and Marcipar, 2019).

**Host-Derived RNS and ROS in Trypanosoma cruzi Infection**

Apart from the previously mentioned reports on the role of NO in immune suppression during T. cruzi infection, several groups investigated the dual role of NO in controlling parasite burden and as the cause of tissue damage or toxicity. Studies in vitro showed the mediation of TNF and INF-γ in the resistance to T. cruzi infection in both human (Muñoz-Fernández et al., 1992a) and mouse macrophages (Silva et al., 1995) by increased NO production. Another report in vivo infections showed that the production of NO was host-dependent (de Oliveira et al., 1997). Macrophages from mice deficient in the expression of IFN-γ receptor and iNOS showed impaired trypanocidal activity of macrophages (Hölscher et al., 1998). But others reported adverse effects of NO generated by cardiac iNOS during infection that may participate in the pathogenesis of murine chagasic heart disease (Huang et al., 1999), gastrointestinal damage (Ny et al., 1999; Arantes et al., 2004; Ny et al., 2008), heart and spleen damage (Ribeiro et al., 2007), and contribute to neuronal death (Bombeiro et al., 2010). Finally, it was reported that iNOS was not essential to control the infection in mice (Cummings and Tarleton, 2004). Thus, still there are some doubts about the role of NO. This is likely due to the different immunopathogenic mechanisms triggered by different parasite strains in mice as well as the host genetic backgrounds.

There are also divergent results on the role of NOX-2 and ROS during T. cruzi infection. Pioneer works showed that ROS was detected in the portion of the plasma membrane of the macrophages to which the parasites attached, and in the membrane which surrounds endocytic vacuoles containing ingested T. cruzi parasites (de Carvalho and de Souza, 1987). Also, invasion by T. cruzi and an inflammatory milieu affected mitochondrial integrity and contributed to electron transport chain inefficiency and ROS production in cardiomycocytes (Gupta et al., 2009). Moreover, cruzipain, a major T. cruzi cysteine protease favored oxidative burst in murine cells (Guíñazu et al., 2010). Bystander effects of heart-infiltrating phagocytes and CD8+ T cells resulting in cardiac remodeling in chagasic mice by the action of NOX and ROS were also described (Dhiman and Garg, 2011). More recently, using macrophages deficient in the expression of NLR family pyrin domain containing 3 (NLRC3) it was shown that NLRC3-mediated IL-1β/NIK activation was dispensable and compensated by ROS-mediated control of T. cruzi replication and survival in macrophages (Dey et al., 2014). Moreover, NOX-2 deficiency, compromised CD8+ T cell response, leading to increased parasite burden, tissue pathogenesis, and mortality in chagasic mice (Dhiman and Garg, 2014). However, other reports show that T. cruzi needs a signal provided by ROS to infect macrophages (Goes et al., 2016). In the same direction, cyclophilin 19 released in the host cell cytosol by T. cruzi mediates the increase of ROS, required to boost parasite proliferation in mammalian hosts (Dos Santos et al., 2021).

On the other hand, ONOO−, resulting from the combination of NO and O2−, acts as an intraphagosomal cytotoxin against pathogens, while microbial peroxiredoxins facilitate infectivity via decomposition of macrophage-derived ONOO− (Alvarez et al., 2011). Moreover, it was shown that O2− did not play a critical role in the control of the parasite, but it was important to prevent blood pressure decline during infection with T. cruzi (Santiago et al., 2012).

**ROLE OF SLAMF1 RECEPTOR ON ROS GENERATION AND MDSC EXPANSION DURING Trypanosoma cruzi INFECTION**

The SLAMF1 receptor was shown to play an important role in the context of T. cruzi infection (Figure 2). The SLAM family of receptors is composed of 9 members with a similar structure. SLAMF1-7 genes are located in the same cluster in chromosome 1 and contain intracellular immuno-receptor tyrosine-based activation motif (ITAM). But SLAMF8-9, located nearby both in human and mouse, lack intracellular ITAM motifs. SLAM-family receptors expressed by different immune cells can form homophilic interactions between them, recruiting adaptor proteins as SLAM-associated adaptor (SAP) in T cells that enhance IL-4 and IL-13 production (Davidson et al., 2004). SLAMF1 (CD150), expressed also in HSCs, is a self-ligand that mediates IL-4 production after interaction of an antigen-presenting cell (APC) with a CD4+ T cell. It also regulates natural killer cell (NK/T) differentiation after interaction between double-positive T cells (Sintes and Engel, 2011). In the context of bacterial infection, the interaction of OmpC/F/E. coli with SLAMF1 is required for macrophage phagocytosis and phagosome localization where EWS/FLII activated transcript 2 (EAT2) enhances Phosphatidylinositol-3-phosphate (PI3P) production, activation of NOX-2 and O2− production, which besides antimicrobial activity, is a signaling molecule that modulates cell motility and phagocytosis, thus, in the absence of SLAMF1 the phagocytic process of Gram- bacteria is compromised (van Driel et al., 2016). However, SLAMF1 was not required in infections with a Gram+ bacteria like Staphylococcus aureus (Berger et al., 2010).

We found that BALB/c mice deficient in the expression of SLAMF1 (Slamf1−/−) survived the infection with a lethal dose of the T. cruzi Y strain for which, as observed before, susceptible wild type (WT) BALB/c succumbed to the infection (Calderón et al., 2012). In addition, Slamf1−/− macrophages became more resistant to the infection with the same strain. More recently, we described increased resistance of Slamf1−/− macrophages to the infection with other parasite strains (Dm28c, M6421, 10R26, and Bug2148) except for one (VFRA) (Poveda et al., 2020). This correlated with the increased expression of NOX-2 expression.
and ROS production in Slamf1−/− macrophages infected with all the strains except VFRA compared to the WT. These opposing strain-dependent roles of SLAMF1 in infectivity and ROS production may explain some of the mentioned discrepancies in the chapter above about the role of ROS in T. cruzi infection. Moreover, Slamf1−/− mice infected with the Y strain showed a shift from MDSC expansion to M1 polarization compared to the WT (Poveda et al., 2020), suggesting that SLAMF1 may have a role in emergency myelopoiesis and possibly mediating MDSCs expansion, a possibility that should be explored in the future.

CONCLUSIONS

In T. cruzi infection, immune suppression was described in seminal studies decades ago. First suppression was thought to depend on particular molecules until NO was identified as one of the suppressor mediators in MDSCs. The mechanism of suppression mediated by NO and other RNS is the toxicity caused by protein nitrosylation and/or nitration, which also can cause tissue damage and vasodilation. On the other hand, is essential as an antimicrobial defense in phagolysosomes. Thus, NO has many roles. In T. cruzi infection, the last has been questioned since it was not necessary for controlling infection in certain models. This might be due to particular combinations of parasite and mouse strains, or the development of compensatory mechanisms that help to control infection in the absence of NO production.

In our hands, NO protects from T. cruzi infection, but the expansion of MDSCs that express iNOS is detrimental for infected mice with immunosuppressive effects. In addition, MDSCs expansion is associated with L-arg depletion by Arg1, which causes further suppression. It will be interesting to study the effect of MDSCs expansion inhibition in this model of experimental infection.

Another antimicrobial mechanism in MDSCs is ROS production by NOX-2. Again the role of NOX-2 in T. cruzi infection is controversial. Thus, some reports, like ours, link NOX-2 and resistance to infection, but others claim that ROS production by NOX-2 is needed for parasite proliferation. We believe that an explanation could be that parasites with strong antioxidant defenses can proliferate in the presence of low levels of ROS, but likely they succumb when ROS levels are high.

In humans, the expression of Arg1 by myeloid cells is thought to be restricted to granulocytes. However, there is some evidence that human monocytes/macrophages can express Arg1. Thus, it will be interesting to perform studies to evaluate the plasma levels of L-arg in humans with T. cruzi acute infection and/or in vertical transmission by infected pregnant mothers. If L-arg levels turn out to be low in acute/chronic Chagas disease patients, they could receive drug therapy in combination with L-arg supplementation to eliminate the parasite more efficiently. This may enable in the future to reduce the dose of conventional antiparasitic drugs, which present many secondary effects due to toxicity. Although the excessive expansion of MDSCs is host detrimental, their complete depletion could have adverse effects according to the reported results. In this direction, blocking SLAMF1 interaction with the parasite might be beneficial for the host by skewing MDSCs expansion. Thus, the identification of SLAMF1 parasite ligands can lead to the development of new therapies.

AUTHOR CONTRIBUTIONS

MF and NG wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by “Ministerio de Economía y competitividad/FEDER” (MINECO/FEDER) SAF2015-63868-R and “FEDER/Ministerio de Ciencia, Innovación y Universidades Agencia Estatal de Investigación” (MICINN/FEDER) PGC2018-096132-B-100 to NG, SAF2016-75988-R (MINECO/FEDER) to MF; “Red de Investigación de Centros de Enfermedades Tropicales” (RICET RD12/0018/0004 to MF); Comunidad de Madrid (S-2010/BMD-2332) to MF; and Institutional grants from “Fundación Ramón Areces” and “Banco de Santander”.

REFERENCES

Abad Dar, M., and Holscher, C. (2018). Arginase-1 Is Responsible for IL-13-Mediated Susceptibility to Trypanosoma Cruzi Infection. Front. Immunol. 9, 2790. doi: 10.3389/fimmu.2018.02790

Abidin, B. M., Hammami, A., Stäger, S., and Heinonen, K. M. (2017). Infection-Adapted Emergency Hematopoiesis Promotes Visceral Leishmaniasis. PloS Pathog. 13, e1006422. doi: 10.1371/journal.ppat.1006422

Abrahamsohn, I. A., and Coffman, R. L. (1995). Cytokine and Nitric Oxide Regulation of the Immunosuppression in Trypanosoma Cruzi Infection. J. Immunol. 155, 3955–3963.

Alcaide, P., and Fresno, M. (2004). The Trypanosoma Cruzi Membrane Mucin AgC10 Inhibits T Cell Activation and IL-2 Transcription Through L-Selectin. Int. Immunol. 16, 1363–1375. doi: 10.1093/intimm/dxh138

Aliberti, J. C., Cardoso, M. A., Martins, G. A., Gazzinelli, R. T., Vieira, L. Q., and Silva, J. S. (1996). Interleukin-12 Mediates Resistance to Trypanosoma Cruzi in Mice and Is Produced by Murine Macrophages in Response to Live Tryptomastigotes. Infect. Immun. 64, 1961–1967. doi: 10.1128/iai.64.11.1961-1967.1996

Alvarez, M. N., Peluffo, G., Piacenza, L., and Radi, R. (2011). Intraphagosomal Peroxynitrite as a Macrophage-Derived Cytotoxin Against Internalized Trypanosoma Cruzi: Consequences for Oxidative Killing and Role of Microbial Peroxiredoxins in Infectivity. J. Biol. Chem. 286, 6627–6640. doi: 10.1074/jbc.M110.167247

Angulo, I., de las Heras, F. G., García-Bustos, J. F., Gargallo, D., Muñoz-Fernández, M. A., and Fresno, M. (2000). Nitric Oxide-Derived CD11b + Ly-6g(Gr-1)(+)CD31(ER-MP12)(+) Cells in the Spleen of Cyclophosphamide-Treated Mice: Implications for T-Cell Responses in Immunosuppressed Mice. Blood 95, 212–220. doi: 10.1182/blood.V95.1.212

Apolloni, E., Bronte, V., Mazzoni, A., Serafini, P., Cabrelle, A., Segal, D. M., et al. (2000). Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes. J. Immunol. 165, 6723–6730. doi: 10.4049/immunol.165.12.6723
Arantes, R. M. E., Marche, H. H. F., Bahia, M. T., Cunha, F. Q., Rossi, M. A., and Silva, J. S. (2004). Interferon-Gamma-Induced Nitric Oxide Causes Intrinsic Intestinal Dormancy in Trypanosoma Cruzi-Infected Mice. *Am. J. Pathol.* **164,** 1361–1368. doi: 10.1016/s0002-9440(10)63222-1

Arocena, A. R., Onofrio, L. L., Pellegrini, A. V., Silva, A. E. C., Paroli, A., Cano, R. C., et al. (2014). Myeloid-Derived Suppressor Cells Are Key Players in the Resolution of Inflammation During a Model of Acute Infection. *Eur. J. Immunol.* **44,** 184–194. doi: 10.1007/s001342015

Bandyopadhyay, S., Kar Mahapatra, S., Halder, K., et al. (2015). Toll-Like Receptor 2 Targeted Rectification of Impaired CD8⁺ T Cell Functions in Experimental Leishmaniasis. *Infect Host Protect.* *PloS One* **10**, e0142800. doi: 10.1371/journal.pone.0142800

Belyaev, N. N., Brown, D. E., Diaz, A.-I. G., Rae, A., Jarra, W., Thompson, J., et al. (2012). The Receptor Slamf1 on the Surface of Myeloid Lineage Cells Critically Dependent on IFN-Gamma Signaling During Acute Malaria. *Nat. Immunol.* **13,** 477–485. doi: 10.1038/ni.1869

Berger, S. B., Romero, X., Ma, C., Wang, G., Faubion, W. A., Liao, G., et al. (2010). SLAM Is a Microbial Sensor That Regulates Bacterial Phagosome Functions in Macrophages. *Nat. Immunol.* **11,** 920–927. doi: 10.1038/ni.1931

Bianchini Narde, M., Belli Cassa Domingues, E. L., Ribeiro Cabrera, G., and Marcipar, I. (2019). Vaccines and the Regulatory Arm of the Immune System. *Blackwell, S.* (2010). *The Biochemistry, Measurement and Current Clinical Nomenclature and Characterization Standards.* *Nat. Commun.* **7**, 12150.

Blackwell, S. (2010). The Biochemistry, Measurement and Current Clinical Significance of Asymmetric Dimethylarginine. *Ann. Clin. Biochem.* **47,** 17–28. doi: 10.1258/acy.2009.009196

Boimiero, A. L., D’Imperio Lima, M. R., Chadi, G., and Alvarez, J. M. (2010). Neurodegeneration and Increased Production of Nitrotyrosine, Nitric Oxide Synthase, IFN-Gamma and S100beta Protein in the Spinal Cord of IL-12p40-Deficient Mice Infected With Trypanosoma Cruzi. *Neuroimmunomodulation** **17,** 67–78. doi: 10.1159/000258689

Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., et al. (2016). Recommendations for Myeloid-Derived Suppressor Cell Nomenclature and Characterization Standards. *Nat. Commun.* **7,** 12150. doi: 10.1038/ncomms12150

Bronte, V., Serafini, P., Mazzoni, A., Segal, D. M., and Zanovello, P. (2003). L-Arginine Metabolism in Myeloid Cells Controls T-Lymphocyte Functions. *Trends Immunol.* **24,** 302–306. doi: 10.1016/s1471-4906(03)00132-7

Bronte, V., and Zanovello, P. (2005). Regulation of Immune Responses by L-Arginine Metabolism. *Nat. Rev. Immunol.* **5,** 641–654. doi: 10.1038/nri1668

Cabrera, G., and Marcipar, I. (2019). Vaccines and the Regulatory Arm of the Immune System. *Frontiers in Cellular and Infection Microbiology | www.frontiersin.org August 2021 | Volume 11 | Article 737364*

Cotterell, S. E., Engwerda, C. R., and Kaye, P. M. (2000). Leishmanina Donovani Infection of Bone Marrow Stromal Macrophages Selectively Enhances Myeloopoiesis, by a Mechanism Involving GM-CSF and TNF-Alpha. *Blood* **95,** 1642–1651. doi: 10.1182/blood.v95.5.1642-005k10_1642_1651

Cuervo, H., Guererro, N. A., Carbajosa, S., Beschin, A., De Baetselier, P., Gironés, N., et al. (2011). Myeloid-Derived Suppressor Cells Infiltrate the Heart in Acute Trypanosoma Cruzi Infection. *J. Immunol.* **187,** 2656–2665. doi: 10.4403/jimmunol.1002928

Cuervo, H., Pineda, M. A., Aoki, M. P., Gea, S., Fresno, M., and Gironés, N. (2008). Inducible Nitric Oxide Synthase and Arginase Expression in Heart Tissue During Acute Trypanosoma Cruzi Infection in Mice: Arginase II Is Expressed in Infiltrating CD8⁺ Macrophages. *J. Infect. Dis.* **197,** 1772–1782. doi: 10.1086/529527

Cummings, K. L., and Tarleton, R. L. (2004). Inducible Nitric Oxide Synthase Is Not Essential for Control of Trypanosoma Cruzi Infection in Mice. *Infect. Immun.* **72,** 4081–4089. doi: 10.1128/IAI.72.7.4081-4089.2004

Davidson, D., Shi, X., Zhang, S., Wang, H., Nemer, M., Ono, N., et al. (2004). Genetic Evidence Linking SAP, the X-Linked Lymphoproliferative Gene Product, to Src-Related Kinase FynT in T(H)2 Cytokine Regulation. *Immunity* **21,** 707–717. doi: 10.1016/j.immuni.2004.10.005

de Carvalho, T. U., and de Souza, W. (1987). Cytochemical Localization of NADH and NADPH Oxidases During Interaction of Trypanosoma Cruzi With Activated Macrophages. *Parasitol. Res.** **73,** 213–217. doi: 10.1007/BF00578506

de Oliveira, L., Borges, M. M., Leal, R. C., Assrey, J., and Klotetz, K. J. (1997). Nitric Oxide Involvement in Experimental Trypanosoma Cruzi Infection in Calomys Callosus and Swiss Mice. *Parasitol. Res.* **83,** 762–770. doi: 10.1007/s004360050336

de Souza, W., de Carvalho, T. M. U., and Barrias, E. S. (2010). Review on Trypanosoma Cruzi: Host Cell Interaction. *Int. J. Cell Biol.* **2010,** 295394. doi: 10.1155/2010/295394

Dey, N., Sinha, M., Gupta, S., Gonzalez, M. N., Fang, R., Endsley, J. J., et al. (2014). Caspase-1/ASC Inflammasome-Mediated Activation of IL-1B-ROS-NF-kB Pathway for Control of Trypanosoma Cruzi Replication and Survival Is Dispensable in NLRP3⁻/⁻ Macrophages. *PloS One* **9,** e111595. doi: 10.1371/journal.pone.0111595

Dhiman, M., and Garg, N. I. (2011). NADPH Oxidase Inhibition Ameliorates Trypanosoma Cruzi-Induced Myocarditis During Chagas Disease. *J. Pathol.* **225,** 583–596. doi: 10.1002/path.2975

Dhiman, M., and Garg, N. J. (2014). P47phox⁻/⁻ Mice Are Compromised in Expansion and Activation of CD8⁺ T Cells and Susceptible to Trypanosoma Cruzi Infection. *PloS Pathog.* **10,** e1004516. doi: 10.1371/journal.ppat.1004516

Dos Santos, G. P., Abukawa, F. M., Souza-Melo, N., Bittencourt-Cunha, P., Moraes, C. B., et al. (2018). Cyclophilin 19 Secreted in the Host Cell Cytosol by Trypanosoma Cruzi Promotes ROS Production Required for Parasite Growth. *Cell Microbiol.* **23,** e13295. doi: 10.1111/cmi.13295

Durko, D., and Pulessis, N. (2017). Monocytic Myeloid-Derived Suppressor Cells in Chronic Infections. *Front. Immunol.* **8,** 1895. doi: 10.3389/fimmu.2017.01895

Echeverria, L. E., and Morillo, C. A. (2019). American Trypanosomiasis (Chagas Disease). *Infect. Dis. Clin. North Am.* **33,** 119–134. doi: 10.1016/j.idc.2018.10.015

Evrard, M., Kwok, I. W. H., Chong, S. Z., Teng, K. W. W., Becht, E., Chen, J., et al. (2018). Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. *Immunity* **48,** 364–379.e8. doi: 10.1016/j.immuni.2018.02.002
Fernandez-Gomez, R., Esteban, S., Gomez-Corvera, R., Zoulika, K., and Ouaisi, A. (1998). Trypanosoma Cruzi: The Role of the Nitrergic System in Infected Hosts. J. Immunol. 160, 3471–3479.

Gabrilovich, D. I. (2017). Myeloid-Derived Suppressor Cells. Cancer Immunol. Res. 5, 3–8. doi: 10.1158/2326-6066

Gabrilovich, D. I., Bronte, V., Chen, S.-H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S., et al. (2007). The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Res. 67, 425–425. doi: 10.1158/0008-5427.CAN-06-3037

Gabrilovich, D. I. and Nagaraj, S. (2009). Myeloid-Derived Suppressor Cells as Regulators of the Immune System. Nat. Rev. Immunol. 9, 162–174. doi: 10.1038/nri2500

Gamba, J. C., Roldán, C., Procheto, E., Lusi, G., Bontempi, I., Poncini, C. V., et al. (2021). Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against Trypanosoma Cruzi. Front. Cell. Infect. Microbiol. 11, 671104. doi: 10.3389/fcimb.2021.671104

Gazzinelli, R. T., Oswald, I. P., Hieny, S., James, S. L., and Sher, A. (1992). The Regulation of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Hosts. Cancer Res. 66, 1123–131. doi: 10.1158/0008-5472.CAN-95-1299

Hernañez-Munain, C., De Diego, J. L., Alcina, A., and Fresno, M. (1999). The Terminology Issue for Myeloid-Derived Suppressor Cells. J. Immunol. 163, 616–616. doi: 10.1158/0008-5472.CAN-99-00340.x

Hölsher, C., Kühler, G., Müller, U., Mossmann, H., Schaub, G. A., and Brombacher, F. (1998). Defective Nitric Oxide Efferon Functions Lead to Extreme Susceptibility of Trypanosoma Cruzi Infected Mice Deficient in Gamma Interferon Receptor or Inducible Nitric Oxide Synthase. Infect. Immun. 66, 1208–1215. doi: 10.1128/IAI.66.3.1208-1215.1998

Huang, H., Chen, J., Wittner, M., Jelicks, L. A., Morris, S. A., Factor, S. M., et al. (1999). Expression of Cardiac Cytokines and Inducible Form of Nitric Oxide Synthase (NOS2) in Trypanosoma Cruzi-Infected Mice. J. Mol. Cell Cardiol. 31, 75–88. doi: 10.1006/jmcc.1998.0848

Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Brombacher, J., et al. (2006). Gr-1+CD11b+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced Regulatory Cells and T-Cell Anergy in Tumor-Bearing Hosts. Cancer Res. 66, 1123–131. doi: 10.1158/0008-5472.CAN-05-1299

Kawakami, M., Tsuchimi, H., Kumakawa, T., Abe, H., Hirai, M., Kurosawa, S., et al. (1990). Levels of Serum Granulocyte Colony-Stimulating Factor in Patients With Infections. Blood 76, 1962–1964. doi: 10.1182/blood.V76.10.1966.1962

Kierszenbaum, F. (1982). Immunologic Deficiency During Experimental Chagas' Disease (Trypanosoma Cruzi Infection): Role of Adherent, Nonsecretive Esterase-Positive Splenic Cells. J. Immunol. 129, 2202–2205

Kierszenbaum, F., de Diego, J. L., Fresno, M., and Sztein, M. B. (1998). Inhibitory Effects of the Trypanosoma Cruzi Membrane Glycoprotein AGC10 on the Expression of IL-2 Receptor Chains and Secretion of Cytokines by Subpopulations of Activated Human T Lymphocytes. Eur. J. Immunol. 29, 1684–1691. doi: 10.1002/1097-0232(199905)29:5<1684::AID-IMMU1684>3.0.CO;2-7

Kierszenbaum, F., Fresno, M., and Sztein, M. B. (2002). The Trypanosoma Cruzi Membrane Glycoprotein AGC10 Inhibits Human Lymphocyte Activation by a Mechanism Preceding Translation of Both, Interleukin-2 and Its High-Affinity Receptor Subunits. Mol. Biochem. Parasitol. 125, 91–101. doi: 10.1016/S0166-6851(02)00217-7

Knobel, C. P., Martinez, F. F., Diaz Lujan, C., Fretes, R. E., Theumer, M. G., et al. (2017). 3-Hydroxykynurenine, a Tryptophan Metabolite Generated During the Infection, Is Active Against Trypanosoma Cruzi. ACS Med. Chem. Lett. 8, 757–761. doi: 10.1021/acsmcl.7b00169

Knobel, C. P., Martinez, F. F., Acosta Rodriguez, E. V., Altamirano, A., Rivarola, H. W., Diaz Lujan, C., et al. (2011). 3-Hydroxy Kynurenine Treatment Controls T Cell Replication and the Inflammatory Pathology Preventing the Clinical Symptoms of Chronic Chagas Disease. PLoS One 6, e26550. doi: 10.1371/journal.pone.0026550

Knobel, C. P., Martinez, F. F., Fretes, R. E., Lujan, C. D., Theumer, M. G., Cervi, L., et al. (2010). Indoleamine 2,3-Dioxygenase (IDO) Is Critical for Host Resistance Against Trypanosoma Cruzi. FASEB J. 24, 2689–2701. doi: 10.1096/fj.09-150920

Kumar, V., Patel, S., Teytakov, E., and Gabrilovich, D. I. (2016). The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol. 37, 208–220. doi: 10.1016/j.it.2016.01.004

Kusmartsev, S. A., Li, Y., and Chen, S. H. (2000). Gr-1+ Myeloid Cells Derived From Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation. J. Immunol. 165, 779–785. doi: 10.4049/jimmunol.165.2.779

Lopez, H. M., Tanner, M. K., Kierszenbaum, F., and Sztein, M. B. (1993). Alterations Induced by Trypanosoma Cruzi in Active Mouse Lymphocytes. Parasite Immunol. 15, 273–280. doi: 10.1111/j.1365-3604.1993.tb00610.x

Marigo, I., Dolcetti, L., Serafini, F., Zanovello, P., and Bronte, V. (2008). Tumor-Induced Tolerance and Immune Suppression by Myeloid Derived Suppressor Cells. Immune. Rev. 222, 162–179. doi: 10.1111/j.1600-065X.2008.00620.x

Mattila, J. T., Ojo, O. O., Kepka-Lenhart, D., Marino, S., Kim, J. H., Eum, S. Y., et al. (2013). Microenvironments in Tuberculous Granulomas are Delineated by Distinct Populations of Macrophage Subsets and Expression of Nitric Oxide Synthase and Arginase Isoforms. J. Immunol. 191, 773–784. doi: 10.4049/jimmunol.1300113

Mills, C. D., Kincade, K., Alt, J. M., Heilmann, M. J., and Hill, A. M. (2000). M1/M2 Macrophages and the Th1/Th2 Paradigm. J. Immunol. 164, 6166–6173. doi: 10.4049/jimmunol.164.12.6166

Mirkovic, A. M., Galelli, A., Allison, A. C., and Modabber, F. Z. (1986). Increased Myelopoiesis During Leishmania Major Infection in Mice: Generation of “Safe Targets”, a Possible Way to Evade the Effector Immune Mechanism. Clin. Exp. Immunol. 64, 1–7.
Ostrand-Rosenberg, S. (2010). Myeloid-Derived Suppressor Cells: More Than Just a Play on Words. J. Immunol. 184, 1065–1071. doi: 10.4049/jimmunol.1005012

Motran, C., Gruppi, A., Vallo, C. M., Pistoresi-Palencia, M. C., and Serra, H. M. (1996). Involvement of Accessory Cells in the Trypanosoma Cruzi-Induced Inhibition of the Polyclonal Response of T Lymphocytes. Parasite Immunol. 18, 43–48. doi: 10.1111/j.1365-3204.1996.015-5.x

Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gyselmen, C., Beschin, A., et al. (2008). Identification of Discrete Tumor-Induced Myeloid-Derived Suppressor Cell Subpopulations With Distinct T Cell-Suppressive Activity. Blood 111, 4233–4244. doi: 10.1182/blood-2007-07-099226

Munder, M., Mollinedo, F., Calafat, J., Canchado, J., Gil-Lamaignere, C., Fuentes, J. M., et al. (2005). Arginase I Is Constitutively Expressed in Human Granulocytes and Participates in Fungicidal Activity. Blood 105, 2549–2556. doi: 10.1182/blood-2004-07-2521

Muñoz-Fernández, M. A., Fernández, M. A., and Fresno, M. (1992a). Activation of Human Macrophages for the Killing of Intracellular Trypanosoma Cruzi by TNF-Alpha and IFN-Gamma Through a Nitric Oxide-Dependent Mechanism. Immunol. Lett. 33, 35–40. doi: 10.1016/0165-2478(92)90090-b

Muñoz-Fernández, M. A., Fernández, M. A., and Fresno, M. (1992b). Synergism Between Tumor Necrosis Factor-Alpha and Interferon-Gamma on Macrophage Activation for the Killing of Intracellular Trypanosoma Cruzi Through a Nitric Oxide-Dependent Mechanism. Eur. J. Immunol. 22, 301–307. doi: 10.1002/eji.1830220203

Nabors, G. S., and Tarleton, R. L. (1991). Differential Control of IFN-Gamma and IL-2 Production During Trypanosoma Cruzi Infection. J. Immunol. 146, 3591–3598.

Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., et al. (2008). NADPH Oxidases: An Essential Everything in the Control of T Cell Response But Also Affecting Cells With Regulatory/Suppressor Phenotype. Oncotarget 8, 58003–58020. doi: 10.18632/oncotarget.18217

Rassi, A., Rassi, A., and Marcondes de Rezende, J. (2012). American Trypanosomiasis (Chagas Disease). Infect. Dis. Clin. North Am. 26, 275–291. doi: 10.1016/j.idc.2012.03.002

Ribeiro, D. A., Calvi, S. A., Persi, M. E., de Carvalho, T. B., Caetano, P. K., et al. (2007). DNA Damage and Nitric Oxide Synthesis in Experimentally Infected Balb/c Mice With Trypanosoma Cruzi. Exp. Parasitol. 116, 296–301. doi: 10.1016/j.exppara.2006.12.007

Rodrigues, J. C. F., Godinho, J. L. P., and de Souza, W. (2014). Biology of Human Pathogenic Trypanosomatids: Epidemiology, Lifecycle and Ultrastructure. Subcell Biochem. 74, 1–42. doi: 10.1007/978-94-007-7305-9_1

Sanoja, C., Carbajosa, S., Fresno, M., and Gironès, N. (2013). Analysis of the Dynamics of Infiltrating CD4(+) T Cell Subsets in the Heart During Experimental Trypanosoma Cruzi Infection. PloS One 8, e65820. doi: 10.1371/journal.pone.0065820

Sánchez, H. C., Gonzalez Lombana, C. Z., Macedo, J. P., Utsch, L., Tafuri, W. L., Campoy-Camacho, S. L., et al. (2012). NADPH Phagocyte Oxidase Knockout Mice Control Trypanosoma Cruzi Proliferation, But Develop Circulatory Collapse and Succumb to Infection. PLoS Negl. Trop. Dis. 6, e1492. doi: 10.1371/journal.pntd.0001492

Schmid, M., Zimara, N., Wege, A. K., and Ritter, U. (2014). Myeloid-Derived Suppressor Cell Functionality and Interaction With Leishmania Major Parasites Differ in C57BL/6 and BALB/c Mice. J. Immunol. 144, 3295–3306. doi: 10.4049/jimmunol.14344335

Silva, J. S., Morrissey, P. J., Grabstein, K. H., Mohler, K. M., Anderson, D., and Reed, S. G. (1992). Interleukin 10 and Interferon Gamma Regulation of Experimental Trypanosoma Cruzi Infection. J. Exp. Med. 175, 169–174. doi: 10.1084/jem.175.1.169

Silva, J. S., Vespa, G. N., Cardoso, M. A., Aliberti, J. C., and Cunha, F. Q. (1995). Tumor Necrosis Factor Alpha Mediates Resistance to Trypanosoma Cruzi Infection in Mice by Inducing Nitric Oxide Production in Infected Gamma Interferon-Activated Macrophages. Infect. Immun. 63, 4862–4867. doi: 10.1128/iai.63.12.4862-4867.1995

Sinha, P., Clements, K. V., and Ostrander-Rosenberg, S. (2005). Reduction of Myeloid-Derived Suppressor Cell Functionality and Interaction With Leishmania Major Parasites Differ in C57BL/6 and BALB/c Mice. Eur. J. Immunol. 34, 301–307. doi: 10.1002/eji.200434421

Song, X., Krelin, Y., Dvorkin, T., Bjorkdahl, O., Segal, S., Dinarello, C. A., et al. (2005). CD11b/Gr1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1beta-Secreting Cells. J. Immunol. 75, 8200–8208. doi: 10.4049/jimmunol.175.12.8200

Sponaas, A.-M., Freitas do Rosario, A. P., Voisine, C., Mastelic, B., Thompson, J., Koenring, S., et al. (2009). Migrating Monocytes Recruited to the Spleen Play an Important Role in Control of Blood Stage Malaria. Blood 114, 5522–5531. doi: 10.1182/blood-2009-04-217489

Strauss, L., Sangaletti, S., Consonni, F. M., Szebeni, G., Morlacchi, S., Totaro, M. G., et al. (2014). RORC1 Regulates Tumor-Promoting “Emergency” Granulocyte-Monocyteopoiesis. Cancer Cell 28, 253–269. doi: 10.1016/j.ccell.2015.07.006

Su, Y., Qiu, Y., Qiu, Z., and Qu, P. (2019). MicroRNA Networks Regulate the Activation Molecule Family 1 (SLAMFI) Receptor With Trypanosoma Cruzi Is Strain-Dependent and Affects NADPH Oxidase Expression and Activity. PloS Negl. Trop. Dis. 14, e008608. doi: 10.1371/journal.pntd.0008608

Procheto, E., Roldán, C., Bontempi, I. A., Bertoná, D., Peverengo, L., Vicco, M. H., et al. (2017). Trans-Sialidase-Based Vaccine Candidate Protects Against Trypanosoma Cruzi Infection, Not Only Inducing an Effector Immune Response But Also Affecting Cells With Regulatory/Suppressor Phenotype. Oncotarget 8, 58003–58020. doi: 10.18632/oncotarget.18217

Frontiers in Cellular and Infection Microbiology | www.frontiersin.org August 2021 Volume 11 Article 737364

Fresno and Gironés MDSCs and T. cruzi Infection

Mitroulis, I., Kalafati, L., Hajishengallis, G., and Chavakis, T. (2018). Myelopoiesis in the Context of Innate Immunity. J. Innate Immun. 10, 365–372. doi: 10.1159/000485006

Poncini, C. V., and González-Cappa, S. M. (2017). Dual Role of Monocyte-Derived Dendritic Cells in Trypanosoma Cruzi Infection. Eur. J. Immunol. 47, 1936–1948. doi: 10.1002/eji.201646830

Poveda, C., Herreros-Cabello, A., Callejas-Hernández, F., Osuna-Pérez, J., Maza, M. C., Chillón-Marinás, C., et al. (2020). Interaction of Signaling Lymphocytes...
Thomas, A. C., and Mattila, J. T. (2014). "Of Mice and Men": Arginine Metabolism in Macrophages. *Front. Immunol.* 5, 479. doi: 10.3389/fimmu.2014.00479

Torrico, F., Heremans, H., Rivera, M. T., Van Marck, E., Billiau, A., and Carlier, Y. (1991). Endogenous IFN-Gamma is Required for Resistance to Acute Trypanosoma Cruzi Infection in Mice. *J. Immunol.* 146, 3626–3632.

van Driel, B. J., Liao, G., Engel, P., and Terhorst, C. (2016). Responses to Microbial Challenges by SLAMF Receptors. *Front. Immunol.* 7, 4. doi: 10.3389/fimmu.2016.00004

Van Ginderachter, J. A., Beschin, A., De Baetselier, P., and Raes, G. (2010). Myeloid-Derived Suppressor Cells in Parasitic Infections. *Eur. J. Immunol.* 40, 2976–2985. doi: 10.1002/eji.201040911

Voisin, M. B., Buzoni-Gatel, D., Bout, D., and Velge-Roussel, F. (2004). During Acute Toxoplasmosis. *Infect. Immun.* 72 (9), 5487–5492. doi: 10.1128/IAI.72.9.5487-5492.2004

Wang, S., Song, R., Wang, Z., Jing, Z., Wang, S., and Ma, J. (2018). S100A8/A9 in Inflammation. *Front. Immunol.* 9, 1298. doi: 10.3389/fimmu.2018.01298

World Health Organization Chagas Disease (American Trypanosomiasis). Available at: https://www.who.int/health-topics/chagas-disease#tab=tab_1.

Youn, J.-I., Nagaraj, S., Collazo, M., and Gabrilovich, D. I. (2008). Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. *J. Immunol.* 181, 5791–5802. doi: 10.4049/jimmunol.181.8.5791

Zhao, Y., Wu, T., Shao, S., Shi, B., and Zhao, Y. (2016). Phenotype, Development, and Biological Function of Myeloid-Derived Suppressor Cells. *Oncoimmunology* 5, e1004983. doi: 10.1080/2162402X.2015.1004983

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Fresno and Gironès. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.